Business Wire

GC Pharma Announces EMA Grants Orphan Drug Designation to Hunterase ICV, The World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II Administered by ICV ...

YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (006280.KS) today announced that the European Medicines Agency (EMA) granted orphan drug designation (ODD) to Hunterase ICV (intracerebroventricular, ...
Financial Post

Announcing Marketing Approval for Hunterase ICV Injection 15 mg, the World's First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered ...

YONGIN, South Korea — GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, and Clinigen K.K. (“Clinigen”), headquartered in Tokyo, has ...